India's tuberculosis (TB) incidence has recently been reduced by 21%, almost double the pace observed globally, as per the World Health Organization's Global TB Report 2025.
Similarly, India's TB mortality rate has decreased, reflecting a near-tenfold increase in government funding to the TB program, which has focused on high-risk areas such as Uttar Pradesh, Maharashtra, Bihar, Madhya Pradesh, and Delhi.
Since its launch in December 2024, India's flagship TB elimination mission, the TB Mukt Bharat Abhiyan, has achieved extensive reach, screening over 19 crore vulnerable individuals across the country, leading to the detection of over 24.5 lakh TB patients, including 8.61 lakh asymptomatic TB cases.
Since TB is a vaccine-preventable disease, India offers access to the 100-year-old Bacille Calmette-Guérin vaccine.
These proactive approaches draw on both global and local evidence, underscoring India's commitment to science-based solutions to reduce the severity of this disease.
Unfortunately, the provisional data from the U.S. CDC for 2024 showed 8% increase from 2023, reaching the highest count since 2011, with rates rising across most age groups.
However, the CDC's week #49 data indicates a position trend in 2025, with only 8,489 TB cases confirmed as of December 6, 2025.
While access to the BCG vaccine in the U.S. is limited, recent shortages have been resolved with recombinant versions like rBCG.
As of December 13, 2025, the CDC doesn't recommend it for general use because of false-positive TB skin test results. However, healthcare providers can access the vaccine through special programs when visiting TB-outbreak areas in India.














